Anaphylaxis Treatment Market Report 2026

The anaphylaxis treatment market size has grown strongly in recent years. It will grow from $6.59 billion in 2025 to $7.05 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing diagnosis of allergic disorders, established emergency treatment standards, availability of epinephrine-based therapies, expansion of hospital pharmacy networks, growing physician awareness.

The anaphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $9.33 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing investments in advanced drug delivery systems, rising focus on patient-centric treatment solutions, expansion of digital pharmacy platforms, growing demand for fast-acting medications, increasing global allergy prevalence. Major trends in the forecast period include increasing use of auto-injectable epinephrine products, rising adoption of multi-drug treatment protocols, growing emphasis on rapid intervention, expansion of retail and online distribution channels, enhanced focus on treatment accessibility.

The increasing prevalence of food allergies is expected to drive the growth of the anaphylaxis treatment market in the coming years. Food allergies are immune-mediated adverse reactions that occur when the body mistakenly identifies specific food proteins as harmful, triggering responses that range from mild symptoms to life-threatening anaphylaxis. One key factor contributing to the rise in food allergies is greater environmental and dietary exposure during early childhood, which can influence immune system development and increase sensitivity to common food allergens. Anaphylaxis treatment addresses this growing clinical need by providing rapid, life-saving intervention that mitigates severe allergic reactions and enhances patient safety amid rising food allergy incidence. For example, in May 2024, the Food Standards Agency, a UK-based government department, reported that approximately 6% of UK adults - around 2.4 million people - had clinically confirmed food allergies. Consequently, the rising prevalence of food allergies is propelling the growth of the anaphylaxis treatment market.

Key companies in the anaphylaxis treatment market are focusing on developing innovative products, such as epinephrine injections, to improve emergency response and patient outcomes. Epinephrine injections are life-saving medications used in severe allergic reactions, capable of rapidly reversing symptoms such as airway constriction, low blood pressure, and hives. For instance, in March 2023, American Regent Inc., a US-based pharmaceutical company, launched a sulfite-free epinephrine injection USP. This product is suitable for subcutaneous, intramuscular, and intravenous administration and contains no sulfites or preservatives. Epinephrine is also recommended for adult patients experiencing hypotension associated with septic shock to raise mean arterial blood pressure.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. This acquisition allows Amgen to diversify its product portfolio and provide treatments for severe inflammatory, autoimmune, and rare disorders. Through this acquisition, Amgen aims to leverage biological therapies to treat patients with life-threatening conditions. Horizon Therapeutics Plc is an Ireland-based biopharmaceutical company.

Major companies operating in the anaphylaxis treatment market are Merck & Co. Inc., Novartis International AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., ALK-Abelló A/S, Amphastar Pharmaceuticals Inc., Par Pharmaceutical Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, AbbVie Inc., AstraZeneca plc, Boehringer Ingelheim, Eli Lilly and Company, Takeda Pharmaceutical Company Limited.

North America was the largest region in the anaphylaxis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaphylaxis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anaphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the anaphylaxis treatment market by increasing costs of imported drug substances, injector devices, packaging materials, and distribution components. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to reliance on cross-border sourcing. These tariffs are elevating treatment costs and impacting pricing strategies. At the same time, they are encouraging domestic drug manufacturing, regional device assembly, and innovation in cost-effective anaphylaxis treatment delivery systems.

The anaphylaxis treatment market research report is one of a series of new reports that provides anaphylaxis treatment market statistics, including anaphylaxis treatment industry global market size, regional shares, competitors with a anaphylaxis treatment market share, detailed anaphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anaphylaxis treatment industry. This anaphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anaphylaxis treatment involves managing life-threatening allergic reactions caused by foods, insect stings, medications, and latex, where immediate administration of epinephrine is required to reverse the reaction and stabilize the patient’s condition. Rapid medical intervention and comprehensive supportive care are essential to effectively manage the potentially life-threatening symptoms of anaphylaxis.

The primary treatments for anaphylaxis include epinephrine, antihistamines, steroids, beta-antagonists, and others. Epinephrine, a synthetic or naturally derived form of adrenaline, is the first and most critical therapy for anaphylaxis and must be administered as soon as the condition is recognized to prevent the onset of life-threatening symptoms. These treatments are available in forms such as tablets, capsules, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies for conditions including food allergies, pollen allergies, and dust mite allergies.

The anaphylaxis treatment market consists of sales of bronchodilators, corticosteroids, and vasopressors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.